{"id":3145,"date":"2020-09-05T11:48:58","date_gmt":"2020-09-05T11:48:58","guid":{"rendered":"https:\/\/tansan.com.tr\/?page_id=3145"},"modified":"2020-09-05T12:29:02","modified_gmt":"2020-09-05T12:29:02","slug":"uz-dr-gulhan-ipek-deniz","status":"publish","type":"page","link":"https:\/\/tansan.com.tr\/en\/uz-dr-gulhan-ipek-deniz\/","title":{"rendered":"Uz. Dr. G\u00fclhan \u0130pek Deniz"},"content":{"rendered":"<p><strong>K\u0130\u015e\u0130SEL B\u0130LG\u0130LER<\/strong><\/p>\n<ul>\n<li>Do\u011fum tarihi: 19.05.1983<\/li>\n<li>Yabanc\u0131 dil bilgisi: \u0130ngilizce<\/li>\n<\/ul>\n<p><strong>E\u011e\u0130T\u0130M B\u0130LG\u0130LER\u0130<\/strong><\/p>\n<ul>\n<li>Faculty of Medicine: Dicle University<\/li>\n<li>Internal Medicine: Istanbul Training and Research Hospital<\/li>\n<li>T\u0131bb\u0131 Onkoloji Yan Dal: \u0130stanbul \u00dcniversitesi Cerrahpa\u015fa T\u0131p Fak\u00fcltesi<\/li>\n<\/ul>\n<p><strong>\u0130\u015e TECR\u00dcBES\u0130NE A\u0130T B\u0130LG\u0130LER<\/strong><\/p>\n<ul>\n<li>Mardin Nusaybin 2 nolu Sa\u011fl\u0131k Oca\u011f\u0131 2008-2008<\/li>\n<li>\u0130stanbul E\u011fitim ve Ara\u015ft\u0131rma Hastanesi 2008-2013<\/li>\n<li>Gaziosmanpa\u015fa Taksim E\u011fitim Ve Ara\u015ft\u0131rma Hastanesi 2013-2014<\/li>\n<li>\u0130stanbul \u00dcni. Cerrahpa\u015fa T\u0131p Fak.( 2014-2017)<\/li>\n<li>Mu\u015f Devlet Hastanesi(2017-2017 , e\u015f durumu ile \u0130stanbul atama)<\/li>\n<li>\u0130stanbul \u015ei\u015fli Hamidiye Etfal E\u011fitim ve Ara\u015ft\u0131rma Hastanesi (2017- 2020)<\/li>\n<li>\u00d6zel Tansan Poliklini\u011fi 2020 &#8211; &#8230;<\/li>\n<\/ul>\n<p><strong>KL\u0130N\u0130K ARA\u015eTIRMALARLA \u0130LG\u0130L\u0130 GENEL B\u0130LG\u0130LER<\/strong><\/p>\n<p><strong>ANNAR 42756493BLC3002<\/strong><\/p>\n<p>\u0130leri Evre \u00dcrotelyal Kanseri ve Fibroblast B\u00fcy\u00fcme Fakt\u00f6r\u00fc Resept\u00f6r\u00fc Gen Aberasyonlar\u0131 olan Hastalar\u0131 Belirlemeye Y\u00f6nelik Biyobelirte\u00e7 \u00c7al\u0131\u015fmas\u0131<\/p>\n<p>Yard\u0131mc\u0131 ara\u015ft\u0131rmac\u0131;<\/p>\n<p><strong>PDR00l<\/strong><\/p>\n<p>\u0130lerlemi\u015f maligniteleri olan hastalarda PDR00 I uygulamas\u0131n\u0131n g\u00fcvenlilik ve etkilili\u011fine ili\u015fkin a\u00e7\u0131k etiketli, \u00e7ok merkezli bir Faz I\/ II \u00e7al\u0131\u015fma<\/p>\n<p><strong>MON-7<\/strong><\/p>\n<p>Honnon resept\u00f6r pozitif, HER2-negatif, ilerlemi\u015f meme kanseri olan premenopozal kad\u0131nlar\u0131n tedavisinde tamoksifen ve goserelin ya da steroidal olmayan aromataz inhibit\u00f6r\u00fc (NSAI) ve goserelin ile birlikte kullan\u0131lan LEE0l 1 ya da plasebonun incelendi\u011fi Faz III, randomize, \u00e7ift k\u00f6r, plasebo kontroll\u00fc \u00e7al\u0131\u015fma<\/p>\n<p><strong>Mon-2<\/strong><\/p>\n<p>Daha \u00f6nce ileri evre hastal\u0131k i\u00e7in tedavi g\u00f6rmemi\u015f, hormon resept\u00f6r\u00fc pozitif, HER2 negatif ileri evre meme kanseri olan postmenopozal kad\u0131nlar\u0131n tedavisi i\u00e7in letrozol ile kombinasyon halinde LEE0l l &#8216;e ili\u015fkin randomize, \u00e7ift k\u00f6r, plasebo kontroll\u00fc \u00e7al\u0131\u015fma<\/p>\n<p><strong>MON-3<\/strong><\/p>\n<p>\u00d6ncesinde tedavi almam\u0131\u015f ya da sadece bir seri endokrin tedavi alm\u0131\u015f hormon resept\u00f6r pozitif, HER2-negatif ileri evre meme kanseri olan erkeklerin ve postmenopozal kad\u0131nlar\u0131n tedavisinde ribosiklib ile birlikte fulvestrant\u0131n kullan\u0131ld\u0131\u011f\u0131 randomize, \u00e7ift k\u00f6r, plasebo kontroll\u00fc \u00e7al\u0131\u015fma<\/p>\n<p><strong>MCSllO<\/strong><\/p>\n<p>\u0130leri Evre \u00dc\u00e7l\u00fc Negatif Meme Kanserinde (TNBC) MCSl 10 ile birlikte karboplatin ve gemsitabinin kullan\u0131ld\u0131\u011f\u0131 randomize, faz II \u00e7al\u0131\u015fma<\/p>\n<p><strong>BOLER0-4<\/strong><\/p>\n<p>\u00d6strojen resept\u00f6r\u00fc pozitif, HER2 negatif, metastatic veya loca! ileri meme kanserli, postmenopozal kad\u0131nlar\u0131n tedavisinde Everolimus &#8216;un Letrozol ile combine edildi\u011fi, a\u00e7\u0131k etiketli, tek kollu, faz II \u00e7al\u0131\u015fma<\/p>\n<p><strong>BOLER0-6<\/strong><\/p>\n<p>\u00d6strojen resept\u00f6r pozitif, loca! olarak ilerlemi\u015f, n\u00fckseden veya metastatic meme kanseri olan postmenopozal kad\u0131nlar\u0131n tedavisinde, daha \u00f6nceki letrozol veya anastrozol uygulamas\u0131 neticesinde n\u00fcks veya progresyonu takiben eksemestan ile kombinasyon halinde everolimus veya kapesitabinin kar\u015f\u0131la\u015ft\u0131r\u0131ld\u0131\u011f\u0131, \u00fc\u00e7 kollu, randomize, a\u00e7\u0131k etiketli bir faz II \u00e7al\u0131\u015fma<\/p>\n<p><strong>I3Y-MC-JPBM<\/strong><\/p>\n<p>Daha \u00d6nce Sistemik Tedavi Almam\u0131\u015f, Hormon Resept\u00f6r-Pozitif, HER2-Negatif, Menapoz-Sonras\u0131 Lokal Rek\u00fcrren ya da Metastatik Meme Kanserli Kad\u0131nlarda, Nonsteroidal Aromataz Inhibitorleri (Anastrozole Yada Letrozole) ile birlikte bir CDK4\/6 \u0130nhibit\u00f6r\u00fc olan L Y2835219 ya da Plasebonun Kar\u015f\u0131la\u015ft\u0131r\u0131ld\u0131\u011f\u0131 Plasebo Kontroll\u00fc, Randomize, \u00c7ift-K\u00f6r, Faz 3 \u00c7al\u0131\u015fma<\/p>\n<p><strong>I3Y-MC-JPBK JUN\u0130PER<\/strong><\/p>\n<p>Platin bazl\u0131 kemoterapiden sonra progresyon g\u00f6steren KRAS mutasyonu saptanm\u0131\u015f Evre IV k\u00fc\u00e7\u00fck h\u00fccreli d\u0131\u015f\u0131 akci\u011fer kanseri hastalar\u0131nda,Abemaciclib ve en iyi destekleyici tedavi ile Erlotinib ve en iyi destekleyici tedavinin kar\u015f\u0131la\u015ft\u0131r\u0131ld\u0131\u011f\u0131, Randomize, Faz 3 \u00e7al\u0131\u015fma<\/p>\n<p><strong>14T-MC-JVDC<\/strong><\/p>\n<p>Platin bazl\u0131 tedavi s\u0131ras\u0131nda ya da sonras\u0131nda progresyon g\u00f6zlenen,lokal ileri ya da cerrahi rezeke edilemeyen ya da metastatik \u00fcrotelyal h\u00fccreli karsinom hastalar\u0131nda,Ramusirumab ile Dosetaksel ve Plasebo ile Dosetaksel&#8217;in kar\u015f\u0131la\u015ft\u0131r\u0131ld\u0131\u011f\u0131 plasebo-kontroll\u00fc,Randomize, \u00c7ift-K\u00f6r,Faz 3 \u00c7al\u0131\u015fma<\/p>\n<p><strong>14D-MC-JTJH<\/strong><\/p>\n<p>Yayg\u0131n evre k\u00fc\u00e7\u00fck h\u00fccreli akci\u011fer kanserli hastalarda LY2606368&#8217;nin kullan\u0131ld\u0131\u011f\u0131 bir Faz 2 \u00e7al\u0131\u015fma.<\/p>\n<p><strong>13Y-MC-JPCE<\/strong><\/p>\n<p>Evre IV K\u00fc\u00e7\u00fck H\u00fccreli D\u0131\u015f\u0131 Akci\u011fer ya da Hormon Resept\u00f6r Pozitif,HER2 Negatif Meme Kanserli Hastalarda Abemaciclib&#8217;in Pembrolizumab ile Kombine Edildi\u011fi Bir Faz 2 \u00c7al\u0131\u015fma.<\/p>\n<p><strong>130-MC-JSBF<\/strong><\/p>\n<p>ileri Evre veya Metastatik Safra Yollar\u0131 Kanser Hastalarda Birinci Basamak tedavi olarak, Sisplatin ve Gemsitabin ile birlikte Ramusirumab veya Merestinib veya Pl.asebo&#8217;nun verildi\u011fi randomize, \u00c7ift-K\u00f6r,Faz 2 \u00c7al\u0131\u015fma.<\/p>\n<p><strong>I4T-MC-JVCZ<\/strong><\/p>\n<p>2.Basamak Metastatik. veya Lokal \u0130leri, rezeke edilemeyen Gastrik ya da Gastro\u00f6zofajeal Bile\u015fkeli Adenokarsinomada, Paklitaksel ile birlikte Alternatif Ramusirumab Dozlar\u0131n\u0131n De\u011ferlendirildi\u011fi Randomize, Faz 2 \u00c7al\u0131\u015fma.<\/p>\n<p><strong>lmvigor130<\/strong><\/p>\n<p>Sisplatin bazl\u0131 kemoterapiye uygun olmayan, tedavi edilmemi\u015f lokal ileri veya metastatik \u00fcrotelyal karsinomlu hastalarda atezolizumab (anti-PD-L 1 antikoru)nun gemsitabin\/karboplatin ile kombinasyonu tek ba\u015f\u0131na gemsitabin\/karboplatin tedavisi ile kar\u015f\u0131la\u015ft\u0131ran faz 3, \u00e7ok merkezli, randomize, plasebo kontroll\u00fc, \u00e7ift k\u00f6r \u00e7al\u0131\u015fma.<\/p>\n<p><strong>IMvigor010<\/strong><\/p>\n<p>-Sistektomi Ard\u0131ndan PD-L 1 Se\u00e7ici, Y\u00fcksek Riskli Kas \u0130nvaziv Mesane Kanserli Hastalarda Adjuvan Tedavi Olarak G\u00f6zlem Yap\u0131lmas\u0131na Kar\u015f\u0131 MPDL3280A (Anti-PD-L 1 Antikor) ile \u0130lgili Bir Faz ili, A\u00e7\u0131k Etiketli, \u00c7ok Merkezli, Randomize \u00c7al\u0131\u015fma<\/p>\n<p><strong>aPDL 1 Basket<\/strong><\/p>\n<p>-ilerlemi\u015f solid t\u00fcmorlerde MPDL3280A&#8217;ya ili\u015fkin a\u00e7\u0131k etiketli, multi-kohortlu, Faz il \u00e7al\u0131\u015fma<\/p>\n<p><strong>SANDPIPER<\/strong><\/p>\n<p>-Aromataz lnhibit\u00f6r\u00fc Tedavisi S\u0131ras\u0131nda Veya Sonras\u0131nda Hastal\u0131\u011f\u0131 N\u00fckseden veya Progresyon G\u00f6r\u00fclen, \u00d6strojen Resept\u00f6r\u00fc Pozitif ve Her2.-Negatif Lokal \u0130leri Veya Metastatik Meme Kanserli Postmenopozal Kad\u0131nlarda Taselisib Art\u0131 Fulvestranta Kar\u015f\u0131 Plasebo Art\u0131 Fulvestrant ile \u0130lgili Faz 111, \u00c7ift K\u00f6r, Plasebo Kontroll\u00fc, Randomize Bir \u00c7al\u0131\u015fma.<\/p>\n<p><strong>RCC<\/strong><\/p>\n<p>Tedavi Uygulanmam\u0131\u015f \u0130leri Renal H\u00fccreli Karsinom Hastalar\u0131nda Sunitinibe Kar\u015f\u0131 Bevasizumab ile Kombinasyon Halinde MPDL328\u00d4A&#8217;y\u0131 (Anti-PD-L 1 Antikoru)<\/p>\n<p>De\u011ferlendiren<\/p>\n<p>Faz 111, A\u00e7\u0131k Etiketli, Randomize Bir \u00c7al\u0131\u015fma.<\/p>\n<p><strong>IMvigor211<\/strong><\/p>\n<p>Lokal ilerlemi\u015f veya metastaik \u00fcrotelyal mesane kanseri hastalar\u0131nda Platin i\u00e7eren kemoterapinin ba\u015far\u0131s\u0131z olmas\u0131ndan sonra MPDL3280A&#8217;n\u0131n (anti-PD-L 1 antikoru) kemoterapiye k\u0131yasla etkililik ve g\u00fcvenlili\u011fini ara\u015ft\u0131ran faz 111, a\u00e7\u0131k etiketli, \u00e7ok merkezli, randomize \u00e7al\u0131\u015fma .<\/p>\n<p><strong>JACOB<\/strong><\/p>\n<p>HER2-Pozitif Metastatik Gastro\u00f6zofageal Bile\u015fke ve Gastrik Kanser Hastalar\u0131nda Trastuzumab ve Kemoterapi ile Kombinasyon Halinde Verilen Pertuzumab&#8217;\u0131n Etkilili\u011finin ve G\u00fcvenlili\u011finin De\u011ferlendirildi\u011fi \u00c7ift K\u00f6r, Plasebo Kontroll\u00fc, Randomize, \u00c7ok Merkezli Faz 111 \u00c7al\u0131\u015fma &#8211;<\/p>\n<p><strong>UMBRELLA ML28851<\/strong><\/p>\n<p>HER2 POZ\u0130TiF ERKEN EVRE MEME KANSERLi HASTALARDA,SUBKUTAN TARSTUZUMAB UYGULAMASINDA HASTA MENNUNIYETININ DE\u011eERLEND\u0130RiLDi\u011ei, A\u00c7IK ET\u0130KETLi.\u00c7OK ULUSLU.\u00c7OK MERKEZLl,FAZ 111 \u00c7ALI\u015eMA .<\/p>\n<p><strong>KAM\u0130LLA MO28231<\/strong><\/p>\n<p>DAHA \u00d6NCE ANTI-HER2 VE KEMOTERAP\u0130 BAZLI TEDAVi ALMI\u015e,HER2 POZiT\u0130F, LOKAL \u0130LERi EVRE VEYA METASTATIK MEME KANSERi HASTALARINDA \u00c7OK MERKEZL\u0130 ,TEK KOLLU TRASTUZUMAB EMTANSINE(T-DM1 )\u00c7ALI\u015eMASI-<\/p>\n<p><strong>JAVEL\u0130N200<\/strong><\/p>\n<p>&#8220;Platin i\u00e7eren ikili tedavinin ard\u0131ndan hastal\u0131kta ilerleme g\u00f6r\u00fclen k\u00fc\u00e7\u00fck h\u00fccreli olmayan akci\u011fer kanseri hastalar\u0131nda, dosetaksel&#8217;e k\u0131yasla avelumab&#8217;\u0131n (MSB0010718C) de\u011ferlendirildi\u011fi bir Faz 111, a\u00e7\u0131k etiketli, \u00e7ok merkezli \u00e7al\u0131\u015fma&#8221;<\/p>\n<p><strong>impower110<\/strong><\/p>\n<p>PDL-1 i\u00e7in se\u00e7ilen, kemoterapi uygulanmam\u0131\u015f evre 4 skuam\u00f6z olmayan k\u00fc\u00e7\u00fck h\u00fccreli-d\u0131\u015f\u0131 akci\u011fer kanseri hastalar\u0131 i\u00e7in sisplatin veya karboplatin + pemetrexed&#8217;e kar\u015f\u0131 MPDL3280A&#8217;n\u0131n (Anti PDL-1 antikoru) de\u011ferlendirildi\u011fi faz 111, a\u00e7\u0131k etiketli, randomize \u00e7al\u0131\u015fma.<\/p>\n<p><strong>MK 3475 -061<\/strong><\/p>\n<p>Platin ve Fluoropirimidin ile Birinci Basamak Tedaviden sonra Progresyon G\u00f6r\u00fclen \u0130lerlemi\u015f Gastrik veya Gastro\u00f6zofageal Bile\u015fke Adenokarsinomu olan G\u00f6n\u00fcll\u00fclerde Pembrolizumab (MK-3475) ile Paklitakselin Kar\u015f\u0131la\u015ft\u0131r\u0131ld\u0131\u011f\u0131 Faz 111, Randomize,<\/p>\n<p>A\u00e7\u0131k Etiketli Klinik \u00c7al\u0131\u015fma.<\/p>\n<p><strong>KEYNOTE-361<\/strong><\/p>\n<p>\u0130leri evre \u00dcrotelyal Karsinomda Kemoterapiye K\u0131yasla Kemoterapi ile Birlikte veya Tek Ba\u015f\u0131na Pembrolizumab\u0131n De\u011ferlendirildi\u011fi Faz 111, Randomize,Kontroll\u00fc \u00c7al\u0131\u015fma<\/p>\n<p><strong>MK 3475 -355<\/strong><\/p>\n<p>Opere Edilemeyen Lokal \u0130leri Veya Metastatik \u00dc\u00e7l\u00fc Negatif Meme Kanseri \u0130\u00e7in Daha \u00d6nce Tedavi Almam\u0131\u015f\u00a0 G\u00f6n\u00fcll\u00fclerde, Pembrolizumab (MK-3475) Art\u0131 Kemoterapi Kombinasyonunun, Plasebo Art\u0131 Kemoterapi \u0130le Kar\u015f\u0131la\u015ft\u0131r\u0131ld\u0131\u011f\u0131 Randomize, \u00c7ift K\u00f6r, Faz 111 \u00c7al\u0131\u015fma<\/p>\n<p><strong>MDV3100-14<\/strong><\/p>\n<p>Daha \u00f6nce kemoterapi g\u00f6rm\u00fc\u015f, kastrasyona diren\u00e7li metastatik prostat kanseri (mKDPK) olan g\u00f6n\u00fcll\u00fclerde Pembrolizumab&#8217;\u0131n (MK3475) Faz il \u00e7al\u0131\u015fmas\u0131.<\/p>\n<p><strong>PROSPER<\/strong><\/p>\n<p>Metastaik Olmayan Kastrasyona Diren\u00e7li Prostat Kanseri Olan Hastalarda Enzalutamid \u0130\u00e7in \u00c7ok Uluslu,Faz 3,Randomize,\u00c7ift K\u00f6r,Plasebo Kontroll\u00fc Etkililik ve G\u00fcvenlilik \u00c7al\u0131\u015fmas\u0131.<\/p>\n<p><strong>Di\u011fer<\/strong><\/p>\n<p>Betul Borku Uysal, Feray AUkbas, Esma Altunoglu, Gulhan ipek Deniz, Duygu Uysal, Harun Uysal, Hanife Usta Atmaca, Yasin Yuksel, Hale Aral, Guven Cetin; M. Cem Ar, Mustafa Boz, Fusun Erdenen, The Effect Of Serum Hepcidin Level On Anemia In Heart Failure,<\/p>\n<p>The Korean Journal ofinternal Medicine Yol. 29, No. 5 (Suppl. 1), PS 0070, WCIM 2014.<\/p>\n<p>1-Ya\u011fbasan Ye\u015filada Belma, \u0130pek Deniz G\u00fclhan, Ar Muhlis Cem, \u00c7etin G\u00fcven, Huq G\u00fcl ben, Sameto\u011flu Fettah (2013). Hodgkin D\u0131\u015f\u0131 Lenfomada Basit Prognostik Fakt\u00f6rler.<\/p>\n<p>39. Ulusal Heniatoloji Kongresi, (Kontrol No: 679731) .<\/p>\n<p>2-Ahmet Baran, G\u00fclhan \u0130pek Deniz, Sibel \u00c7etin Erdamar, Nuray Kepil, Muharrem K\u00f6se, Hande Turna, \u00c7i\u011fdem Papila, Fuat Demirelli (2015).<\/p>\n<p>Kolonoskopi \u0130le Tan\u0131 Konulan Akci\u011fer Kanser Olgusu. 21. Ulusal Kanser Kongresi (PO 18).<\/p>\n<p>3- G\u00fclhan \u0130pek Deniz, Atakan Demir, Bilge \u00d6z, Serg\u00fclen Dervi\u015fo\u011flu, Nil \u00c7omuno\u011flu, Emire Seyahi Kural, Y\u0131ld\u0131z \u015eeng\u00fcl, Hande Turna, \u00c7i\u011fdem Papila, Fuat Demirelli (2015).<\/p>\n<p>Ailesel Akdeniz Ate\u015fi Zemininde Geli\u015fen Malign Mezotelyoma Olgular\u0131.<\/p>\n<p>21. Ulusal Kanser Kongresi (P062).<\/p>\n<p>4-G\u00fclhan \u0130pek Deniz, \u015ee\u0131min G\u00fcven Me\u015fe, Zerrin Calay, Sinem Ko\u00e7ak, Ahmet Baran, Hande Turna, \u00c7i\u011fdem Papila, Fuat Demirelli (2015). Nadir Bir Olgu: Primer N\u00f6roendokrin Meme Karsinomu.<\/p>\n<p>21. Ulusal Kanser Kongresi (P223).<\/p>\n<p>5-Sinem Ko\u00e7ak, G\u00fclhan \u0130pek Deniz, C\u00fcyan Demirkesen, Serg\u00fclen Dervi\u015fo\u011flu, Hande Turna, Mustafa \u00d6zg\u00fcro\u011flu (2015).<\/p>\n<p>\u0130MM\u00dcNSUPRES\u0130F ZEM\u0130NDE METASTAT\u0130K KAPOS\u0130 SARKOM: \u0130K\u0130 OLGU<\/p>\n<p>21. Ulusal Kanser Kongresi (P138).<\/p>\n<p>6-Atakan Demir, Ahmet Baran, Gizem Ayan, \u00d6zcan Y\u0131ld\u0131z, Mesut Y\u0131lmaz, \u015eermin G\u00fcven Me\u015fe, Sinem Ko\u00e7ak, G\u00fclhan \u0130pek Deni\udbc0\udc05, Hande Turna, Mustafa\u00b7\u00d6zg\u00fcro\u011flu, Fuat Hulusi Demirelli<\/p>\n<p>RADYOAKT\u0130F \u0130YOD TEDAV\u0130S\u0130NE REFRAKTER T\u0130RO\u0130D KANSERLER\u0130NDE S\u0130STEM\u0130K TEDAV\u0130LER\u0130N ETK\u0130NL\u0130\u011e\u0130.<\/p>\n<p>21. Ulusal Kanser Kongresi (P321).<\/p>\n<p>7-Ali Can, \u015eermin G\u00fcven Me\u015fe, Atakan Demir, G\u00fclhan \u0130pek Deniz, Mesut Y\u0131lmaz, Ahmet Baran, Sinem Ko\u00e7ak, Z. Hande Turna, \u00c7i\u011fdem Papila, Fuat H. Demirelli .<\/p>\n<p>N\u00d6ROENDOKR\u0130N T\u00dcM\u00d6RLER: TEK MERKEZ 1O YILLIK DENEY\u0130M.<\/p>\n<p>21. Ulusal Kanser Kongresi (P370).<\/p>\n<p>8-\u015eermin G\u00fcven Me\u015fe, Ali Can, Atakan Demir, Teoman Yanmaz, G\u00fclhan \u0130pek Deniz, Mesut Y\u0131lmaz, Sinem Ko\u00e7ak, Ahmet Baran,_ Z. Hande Turna, Mustafa \u00d6zg\u00fcro\u011flu<\/p>\n<p>N\u00dcKS EP\u0130TELYAL OVER KANSER\u0130NDE BEVAS\u0130ZUMAB ETK\u0130NL\u0130\u011e\u0130.<\/p>\n<p>21. Ulusal Kanser Kongresi (P406).<\/p>\n<p>9-G\u00fclhan \u0130pek Deniz, Sinem Ko\u00e7ak, \u015eermin G\u00fcven Me\u015fe, Mesut Y\u0131lmaz, Ahmet Baran, Atakan Demir, Hande Turna, \u00c7i\u011fdem Papila, Fuat Demirelli<\/p>\n<p>HEPATOSEL\u00dcLER KANSERL\u0130 OLGULARDA SORAFEN\u0130B&#8217;\u0130N ETK\u0130NL\u0130K VE TOLERAB\u0130L\u0130TES\u0130<\/p>\n<p>21. Ulusal Kanser Kongresi (P534).<\/p>\n<p>10-Sinem Ko\u00e7ak, G\u00fclhan \u0130pek Deniz , \u015eermin G\u00fcven Me\u015fe, Ahmet Baran, Mesut Y\u0131lmaz, Atakan Demir, Hande Turna, Nil Molinas Mandel, \u00c7i\u011fdem Papila, Fuat Demirelli<\/p>\n<p>YUMU\u015eAK DOKU SARKOMLARINDA PAZOPAN\u0130B&#8217;\u0130N ETK\u0130NL\u0130K VE G\u00dcVENL\u0130\u011e\u0130.<\/p>\n<p>21. Ulusal Kanser Kongresi (P408).<\/p>\n<p>11-G\u00fclhan \u0130pek Deniz, \u015eermin G\u00fcven Me\u015fe, Atakan Demir, Mesut Y\u0131lmaz, Ahmet Baran, Sinem Ko\u00e7ak, Hande Turna, Fuat Demirelli.(2014)<\/p>\n<p>BAZAL H\u00dcCREL\u0130 KARS\u0130NOM NE KADAR SALDIRGAN OLAB\u0130L\u0130R?<\/p>\n<p>1.Geriatrik Onkoloji Kongresi (P005 l ).<\/p>\n<p>12-S-004 ULUSALAKCIGER KANSERLERi KONGRESI 2020<\/p>\n<p>AKC\u0130GER KANSER\u0130NDE HEDEFE Y\u00d6NEL\u0130K TEDAV\u0130LERDE PET\/BT&#8217; N\u0130N YER\u0130<\/p>\n<p>Re\u015fitAkyel 1 , Emre Demirci 2 , G\u00fclhan ipek Deniz l , 1 \u015ei\u015fli Hamidiye Etfal EAH 2 T.C. Yeditepe \u00dcniversitesi Ko\u015fuyolu Hastanesi<\/p>\n<p>13-S-009 ULUSAL AKC\u0130\u011eER KANSERLER\u0130 KONGRES\u0130 2020<\/p>\n<p>K\u00dc\u00c7\u00dcK H\u00dcCREL\u0130 DI\u015eI AKC\u0130GER KANSER\u0130 VE T\u0130ROZ\u0130N K\u0130NAZ \u0130NH\u0130B\u0130T\u00d6RLER\u0130<\/p>\n<p>G\u00fclhan \u0130pek Deniz l , 1 \u015ei\u015fli Hamidiye Etfal EAH<\/p>\n<p>14-Abstract P5-11-19: Ribociclib for the treatment of hormone receptor-positive refractory advanced breast cancer: Managed access programme in Turkey<\/p>\n<p>Umut Demirci, Erhan Gokmen, Yesim Eralp, Seyda Gunduz, Sema Sezgin Goksu, Taner Korkmaz, Osman Kostek, Serdar Turhal, Semra Paydas, Sevgi Topcu, Burcu Cakar, Bulent Karabulut, Ozgur Tanr\u0131 verdi, Burcak Karaca, Gulhan ipek Deniz, Ozkan Alan, Fatma Paksoy Turkoz and Gul Basaran<\/p>\n<p>DOi: 10.1158\/1538-7445.SABCS19-P5-11-19 Published February 2020<\/p>\n<p><strong>Kitap ve Dergi Yazarl\u0131\u011f\u0131<\/strong><\/p>\n<p>1- Mide Kanserinde Adjuvan Tedavi, KANSER G\u00dcNDEM\u0130 Volume: 3\/1, Mart 2015.<\/p>\n<p>T\u00dcRK\u0130YE KANSERLE SAVA\u015e VAKFl,Dr. G\u00fclhan \u0130pek Deniz ,\u0130.\u00dc. Cerrahpa\u015fa T\u0131p Fak\u00fcltesi Medikal Onkoloji Bilim Dal\u0131<\/p>\n<p>2- Abdominal Sarkom un Cerrahi ve Sistemik Tedavisinde G\u00fcncel Yakla\u015f\u0131mlar<\/p>\n<p>B\u00f6l\u00fcm 11, Desmoid T\u00fcm\u00f6rlerin Sistemik Tedavisi, G\u00fclhan \u0130PEK DEN\u0130Z<\/p>\n<p>3- Gastrointestinal Stromal T\u00fcm\u00f6rler ve N\u00f6roendokrin T\u00fcm\u00f6rlere Yakla\u015f\u0131m<\/p>\n<p>B\u00f6l\u00fcm 25, N\u00f6roendokrin T\u00fcm\u00f6r Metastazlar\u0131 ve Sistemik Tedavi, G\u00fclhan \u0130PEK DEN\u0130Z<\/p>\n<p><strong>Konu\u015fmac\u0131<\/strong><\/p>\n<p>MELANOM DI\u015eI C\u0130LT KANSERLER\u0130NDE YEN\u0130L\u0130KLER G\u00fclhan \u0130pek Deniz \u015ei\u015fli Hamidiye Etfal E\u011fitim Ve Ara\u015ft\u0131rma Hastanesi T\u0131bbi Onkoloji, \u0130stanbul<\/p>\n<p>3.GEN\u00c7LERLE ONKOLOJ\u0130YE BAKI\u015e KONGRES\u0130 2020<\/p>","protected":false},"excerpt":{"rendered":"<p>K\u0130\u015e\u0130SEL B\u0130LG\u0130LER Do\u011fum tarihi: 19.05.1983 Yabanc\u0131 dil bilgisi: \u0130ngilizce E\u011e\u0130T\u0130M B\u0130LG\u0130LER\u0130 T\u0131p Fak\u00fcltesi: Dicle \u00dcniversitesi \u0130\u00e7 Hastal\u0131klar\u0131: \u0130stanbul E\u011fitim Ve Ara\u015ft\u0131rma Hastanesi T\u0131bb\u0131 Onkoloji Yan Dal: \u0130stanbul \u00dcniversitesi Cerrahpa\u015fa T\u0131p Fak\u00fcltesi \u0130\u015e TECR\u00dcBES\u0130NE A\u0130T B\u0130LG\u0130LER Mardin Nusaybin 2 nolu Sa\u011fl\u0131k Oca\u011f\u0131 2008-2008 \u0130stanbul E\u011fitim ve Ara\u015ft\u0131rma Hastanesi 2008-2013 Gaziosmanpa\u015fa Taksim E\u011fitim Ve Ara\u015ft\u0131rma Hastanesi 2013-2014<\/p>","protected":false},"author":3,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-3145","page","type-page","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.4 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Uz. Dr. G\u00fclhan \u0130pek Deniz - \u00d6zel Tansan Poliklini\u011fi<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/tansan.com.tr\/en\/uz-dr-gulhan-ipek-deniz\/\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Uz. Dr. G\u00fclhan \u0130pek Deniz - \u00d6zel Tansan Poliklini\u011fi\" \/>\n<meta property=\"og:description\" content=\"K\u0130\u015e\u0130SEL B\u0130LG\u0130LER Do\u011fum tarihi: 19.05.1983 Yabanc\u0131 dil bilgisi: \u0130ngilizce E\u011e\u0130T\u0130M B\u0130LG\u0130LER\u0130 T\u0131p Fak\u00fcltesi: Dicle \u00dcniversitesi \u0130\u00e7 Hastal\u0131klar\u0131: \u0130stanbul E\u011fitim Ve Ara\u015ft\u0131rma Hastanesi T\u0131bb\u0131 Onkoloji Yan Dal: \u0130stanbul \u00dcniversitesi Cerrahpa\u015fa T\u0131p Fak\u00fcltesi \u0130\u015e TECR\u00dcBES\u0130NE A\u0130T B\u0130LG\u0130LER Mardin Nusaybin 2 nolu Sa\u011fl\u0131k Oca\u011f\u0131 2008-2008 \u0130stanbul E\u011fitim ve Ara\u015ft\u0131rma Hastanesi 2008-2013 Gaziosmanpa\u015fa Taksim E\u011fitim Ve Ara\u015ft\u0131rma Hastanesi 2013-2014\" \/>\n<meta property=\"og:url\" content=\"https:\/\/tansan.com.tr\/en\/uz-dr-gulhan-ipek-deniz\/\" \/>\n<meta property=\"og:site_name\" content=\"\u00d6zel Tansan Poliklini\u011fi\" \/>\n<meta property=\"article:modified_time\" content=\"2020-09-05T12:29:02+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Estimated reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"10 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/tansan.com.tr\/uz-dr-gulhan-ipek-deniz\/\",\"url\":\"https:\/\/tansan.com.tr\/uz-dr-gulhan-ipek-deniz\/\",\"name\":\"Uz. Dr. G\u00fclhan \u0130pek Deniz - \u00d6zel Tansan Poliklini\u011fi\",\"isPartOf\":{\"@id\":\"https:\/\/tansan.com.tr\/#website\"},\"datePublished\":\"2020-09-05T11:48:58+00:00\",\"dateModified\":\"2020-09-05T12:29:02+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/tansan.com.tr\/uz-dr-gulhan-ipek-deniz\/#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/tansan.com.tr\/uz-dr-gulhan-ipek-deniz\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/tansan.com.tr\/uz-dr-gulhan-ipek-deniz\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Ana sayfa\",\"item\":\"https:\/\/tansan.com.tr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Uz. Dr. G\u00fclhan \u0130pek Deniz\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/tansan.com.tr\/#website\",\"url\":\"https:\/\/tansan.com.tr\/\",\"name\":\"Tansan Onkoloji - \u00d6zel Tansan Poliklini\u011fi\",\"description\":\"Kanser Te\u015fhis ve Tedavisi\",\"publisher\":{\"@id\":\"https:\/\/tansan.com.tr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/tansan.com.tr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-GB\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/tansan.com.tr\/#organization\",\"name\":\"\u00d6zel Tansan Onkoloji Poliklini\u011fi\",\"url\":\"https:\/\/tansan.com.tr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/tansan.com.tr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/tansan.com.tr\/wp-content\/uploads\/2020\/02\/TansanLogo-1.png\",\"contentUrl\":\"https:\/\/tansan.com.tr\/wp-content\/uploads\/2020\/02\/TansanLogo-1.png\",\"width\":274,\"height\":66,\"caption\":\"\u00d6zel Tansan Onkoloji Poliklini\u011fi\"},\"image\":{\"@id\":\"https:\/\/tansan.com.tr\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Uz. Dr. G\u00fclhan \u0130pek Deniz - \u00d6zel Tansan Poliklini\u011fi","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/tansan.com.tr\/en\/uz-dr-gulhan-ipek-deniz\/","og_locale":"en_GB","og_type":"article","og_title":"Uz. Dr. G\u00fclhan \u0130pek Deniz - \u00d6zel Tansan Poliklini\u011fi","og_description":"K\u0130\u015e\u0130SEL B\u0130LG\u0130LER Do\u011fum tarihi: 19.05.1983 Yabanc\u0131 dil bilgisi: \u0130ngilizce E\u011e\u0130T\u0130M B\u0130LG\u0130LER\u0130 T\u0131p Fak\u00fcltesi: Dicle \u00dcniversitesi \u0130\u00e7 Hastal\u0131klar\u0131: \u0130stanbul E\u011fitim Ve Ara\u015ft\u0131rma Hastanesi T\u0131bb\u0131 Onkoloji Yan Dal: \u0130stanbul \u00dcniversitesi Cerrahpa\u015fa T\u0131p Fak\u00fcltesi \u0130\u015e TECR\u00dcBES\u0130NE A\u0130T B\u0130LG\u0130LER Mardin Nusaybin 2 nolu Sa\u011fl\u0131k Oca\u011f\u0131 2008-2008 \u0130stanbul E\u011fitim ve Ara\u015ft\u0131rma Hastanesi 2008-2013 Gaziosmanpa\u015fa Taksim E\u011fitim Ve Ara\u015ft\u0131rma Hastanesi 2013-2014","og_url":"https:\/\/tansan.com.tr\/en\/uz-dr-gulhan-ipek-deniz\/","og_site_name":"\u00d6zel Tansan Poliklini\u011fi","article_modified_time":"2020-09-05T12:29:02+00:00","twitter_card":"summary_large_image","twitter_misc":{"Estimated reading time":"10 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/tansan.com.tr\/uz-dr-gulhan-ipek-deniz\/","url":"https:\/\/tansan.com.tr\/uz-dr-gulhan-ipek-deniz\/","name":"Uz. Dr. G\u00fclhan \u0130pek Deniz - \u00d6zel Tansan Poliklini\u011fi","isPartOf":{"@id":"https:\/\/tansan.com.tr\/#website"},"datePublished":"2020-09-05T11:48:58+00:00","dateModified":"2020-09-05T12:29:02+00:00","breadcrumb":{"@id":"https:\/\/tansan.com.tr\/uz-dr-gulhan-ipek-deniz\/#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/tansan.com.tr\/uz-dr-gulhan-ipek-deniz\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/tansan.com.tr\/uz-dr-gulhan-ipek-deniz\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Ana sayfa","item":"https:\/\/tansan.com.tr\/"},{"@type":"ListItem","position":2,"name":"Uz. Dr. G\u00fclhan \u0130pek Deniz"}]},{"@type":"WebSite","@id":"https:\/\/tansan.com.tr\/#website","url":"https:\/\/tansan.com.tr\/","name":"Tansan Onkoloji - \u00d6zel Tansan Poliklini\u011fi","description":"Cancer Diagnosis and Treatment","publisher":{"@id":"https:\/\/tansan.com.tr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/tansan.com.tr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-GB"},{"@type":"Organization","@id":"https:\/\/tansan.com.tr\/#organization","name":"\u00d6zel Tansan Onkoloji Poliklini\u011fi","url":"https:\/\/tansan.com.tr\/","logo":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/tansan.com.tr\/#\/schema\/logo\/image\/","url":"https:\/\/tansan.com.tr\/wp-content\/uploads\/2020\/02\/TansanLogo-1.png","contentUrl":"https:\/\/tansan.com.tr\/wp-content\/uploads\/2020\/02\/TansanLogo-1.png","width":274,"height":66,"caption":"\u00d6zel Tansan Onkoloji Poliklini\u011fi"},"image":{"@id":"https:\/\/tansan.com.tr\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/tansan.com.tr\/en\/wp-json\/wp\/v2\/pages\/3145","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/tansan.com.tr\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/tansan.com.tr\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/tansan.com.tr\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/tansan.com.tr\/en\/wp-json\/wp\/v2\/comments?post=3145"}],"version-history":[{"count":8,"href":"https:\/\/tansan.com.tr\/en\/wp-json\/wp\/v2\/pages\/3145\/revisions"}],"predecessor-version":[{"id":3156,"href":"https:\/\/tansan.com.tr\/en\/wp-json\/wp\/v2\/pages\/3145\/revisions\/3156"}],"wp:attachment":[{"href":"https:\/\/tansan.com.tr\/en\/wp-json\/wp\/v2\/media?parent=3145"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}